UCB (OTCMKTS:UCBJF) Shares Gap Up – Time to Buy?
by Amy Steele · The Cerbat GemUCB SA (OTCMKTS:UCBJF – Get Free Report)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $269.30, but opened at $279.1050. UCB shares last traded at $279.1050, with a volume of 201 shares.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on UCBJF. Morgan Stanley restated an “overweight” rating on shares of UCB in a research report on Monday, September 8th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of UCB in a research note on Monday, December 8th. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of “Buy”.
Check Out Our Latest Stock Report on UCB
UCB Stock Performance
The stock has a 50 day moving average of $276.73 and a two-hundred day moving average of $249.37. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.
UCB Company Profile
UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.
Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.